摘要
目的评价贝那普利、缬沙坦对糖尿病肾病（DN）患者血压、24h尿蛋白变化（PRO）、血清单核细胞趋化蛋白-1（MCP-1）及MCP-1及超敏C-反应蛋白（hs-CRP）的影响效果。方法将120例DN患者随机分为观察组、对照组A、对照组B三组，每组40例，三组均给予基础治疗，在此基础上观察组口服贝那普利联合缬沙坦，对照组A口服缬沙坦，对照组B口服贝那普利，疗程均为3个月。观察三组治疗前后血压、PRO、血清MCP-1）及hs—CRP变化。结果三组治疗后血压、尿蛋白、MCP-1及hs—CRP均显著下降（P〈0．05），观察组下降程度大于A、B组（P〈0．05）。结论贝那普利联合缬沙坦治疗DN较单独用药疗效确切，安全性高。
Objective To evaluate the effect of benazepril and valsartan on blood pressure, PRO, serum MCP-1 and hs-CRP in patients with diabetic nephropathy. Methods One hundred and twenty patients with diabetic nephropathy （DN） were randomly divided into three groups： observation group, control group A and control group B, with 40 cases in each group. Three groups were all given basic treatment, and pantients in observation group were treated with benazepril combined with valsartan, patients in control group A took valsartan, patients in control group B took benazepril. The treatment course was 3 months. The changes of blood pressure, 24 h urinary protein changes （ PRO ） , serum MCP-1 and hs-CRP before and after treatment were observed. Results The blood pressure, urine protein, MCP-1 and hs-CRP of the three groups were significantly decreased after treatment （P 〈 0. 05） , and those in the observation group decreased more obviously than those in control group A and B （P 〈 0.05 ）. Conclusions Combined treatment of benazepril and valsartan is effective and safe for DN, compared with monotherapy.
出处
《中国实用医刊》
2012年第19期27-28,共2页
Chinese Journal of Practical Medicine
关键词
糖尿病肾病
联合药物
内分泌
Diabetic nephropathy
Combination of drugs
Endocrine
